Pure Global AI
NCT06231784Completed

Efficacy of the AkkoLens IOL in Patients With Cataract

Prospective, Open-label Clinical Study to Evaluate the Efficacy and Function of the AkkoLens Accommodative Intraocular Acrylic Lens for the Treatment of Cataracts
Vissum, Instituto Oftalmológico de AlicanteClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Cataract
Drug/Device/Intervention
LUMINA IOL
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Vissum, Instituto Oftalmológico de Alicante
Timeline & enrollment
Phase
N/A
Start date
Jun 09, 2016
End date
Dec 01, 2023
Enrollment
25 participants
Primary outcome

Distance Vision measurements,Defocus curve measurements,Accommodation measurements,Depth of focus measurements

Summary

The goal of this observational study is to learn about the verification of the effectiveness
 and visual acuity of LUMINA in patients after lens replacement due to cataracts.
 
 The main questions it aims to answer are:
 
 - Evaluation of the effectiveness of the LUMINA lens in patients after lens replacement
 due to cataracts
 
 - Evaluation of the accommodative power of the LUMINA lens. Participants will have
 cataract surgery and the IOL LUMINA will be implanted in the sulcus.

ICD-10 classifications
Other cataractCataract, unspecifiedComplicated cataractOther specified cataractSenile cataract
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06231784
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06231784 through Pure Global AI's free database. This phase not specified trial is sponsored by Vissum, Instituto Oftalmológico de Alicante and is currently Completed. The study focuses on Cataract. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.